Atrial Fibrillation: Defining Some Unanswered Questions

Naccarelli GV , Shih T-T. , Jalal S. Catheter ablation for the treatment of paroxysmal supraventricular tachycardia. J Cardiovasc Electrophysiol 6:951, 1995

Haverkamp W. , Eckardt L. , Borgreffe M. , Breithardt G. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. Am J Cardiol 80:67G-73G, 1997

Singh BN Controlling cardiac arrhythmias: An overview with a historical perspective . Am J Cardiol 80:4G-15G, 1997

Stevenson WG , Ellison KL , Lefray DC , Friedman PL Ablation therapy for cardiac arrhythmias. Am J Cardiol 80:56G-66G, 1997

Benjamin EJ , Levy D. , Vaziri SM , D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort study. The Framingham Heart Study. JAMA 271:840,1994

Feinberg WM , Blackshear JL , Laupacis A. , Kronmal R. , Hart RG Prevalence, age distribution, and gender of patients with atrial fibrillation . Arch Int Med 155:469,1995

Krahn AD , Manfreda J. , Tate RB , Mathewson FA , Cuddy TE The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 98:476, 1995

Onundarson PT , Thorgeirsson G. , Jonmundsson E. Chronic atrial fibrillation—Epidemiologic features and 14 years follow-up. A case-control study. Eur Heart J 3:521, 1987

Kannel WB , Abbott RD , Savage DD , McNamara PM Coronary heart disease and atrial fibrillation: The Framingham Study . Amer Heart J 106:389, 1983

Sherman DG , Hart RG , Easton JD The secondary prevcntion of stroke in patients with atrial fibrillation . Arch Neurol 43:69, 1986

Wolf PA , Dawber TR , Thomas HE , Kannel WB Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 28:973, 1978

Harrison MJ , Marshall J. Atrial fibrillation. TIAs and completed strokes . Stroke 15:441, 1984

Bogousslavsky J. , Hachinski VC , Boughner DR Fox AJ , Vinucla F. , Barnett HJ Cardiac and arterial lesions in carotid transient ischemic attacks. Arch Neurol 43:223, 1986

Koudstaal PJ , van Gijn J. , Klootwijk AP , van der Merche FG , Kappelle LJ Holter monitoring in patients with transient and focal ischemic attacks of the brain. Stroke 17:192, 1986

Koudstaal PJ Primary and secondary prevention of stroke in patients with nonrheumatic atrial fibrillation. Eur Neurol 34:61, 1994

Koudstaal PJ , Koudstaal A. Stroke prevention in patients with atrial fibrillation: What have we learned? J Cardiovasc Pharmacol Therapeut 3:85, 1998

Morocutti C. , Amabile G. , Fattaposta F. , Nicolosi A. , Matteoli S. , Trappalini M. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke 28:1015,1997

EAFT (European Atrial Fibrillation Trial). Secondary prevention in nonrheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 342:1255, 1993

Grogan M. , Smith HC , Gersh BJ , Wood DL Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 68:1570, 1992

Li Y-G. , Hohnloser SH Update on atrial fibrillation: Restoration of sinus rhythm or ventricular rate control. J Cardiovasc Pharmacol Therapeut 3:185-194, 1998

Coplen SE , Antman EM , Berlin JA , Hewitt P. Chalmers TC Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82:1106,1990

Juul-Moller S. , Edvardsson N. , Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 82:1932,1990

Yusuf S. , Teo KK Approaches to prevention of sudden death: Need for fundamental reevaluation . J Cardiovasc Electrophysiol 2:S233,1991

Singh BN , Vaughan Williams EM. The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol 39:657,1970

Singh BN , Vaughan Williams EM. A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacologic actions on cardiac muscle of MJ1999 and AH 3474. Br J Pharmacol 39: 657, 1970

Singh BN Expanding indications for the use of class III antiarrhythmic agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol 6:887-900,1995

Singh BN Searching for the ideal class III antiarrhythmic agents: How pure should they be? J Cardiovasc Pharmacol Therap 2:239, 1997

Middlekauff HR , Wiener I. , Saxon LA , Stevenson WG Low-dose amiodarone for atrial fibrillation: Time for a prospective study? Ann Intern Med 116:101, 1992

Graboys TB , Podrid PJ , Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J 106:870, 1983

Horowitz LN , Spielman SR , Greenspan AM , Mintz GS , Morganroth J. , Brown R. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 6:1402, 1985

Chun SH , Sager PT , Stevenson WG , Nademanee K. , Middlekauff HR , Singh BN Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 76:47-50,1995

Gosselink AT , Crijns HJ , Van Gelder IC , Hillige H. , Wiesfeld AC , Lie KI Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 267:3289,1992

Gold RL , Haffajee CI , Charos G. , Sloan K. , Baker S. , Alpert JS Amiodarone for refractory atrial fibrillation. Am J Cardiol 57:124, 1986

Brodsky MA , Allen BJ , Walker CJ II, Casey TP , Luckett CR , Henry WL Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 60:572, 1987

Blevins RD , Kerin NZ , Benaderet D. , Frumin H. , Faitel K. , Jarandilla R. , Rubinfire M. Amiodarone in the management of refractory atrial fibrillation. Arch Int Med 147:1401,1987

Zarembski DG , Nolan PE , Slack MK , Caruso AC Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Int Med 155:1885, 1995

Alt E. , Ammer R. , Lehmann G. , Putter K. , Ayers GM , Pasquantonio J. , Schomig A. Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol. Am Heart J 134:419-425, 1997

The AFFIRM Investigators. Atrial fibrillation following investigation of rhythm management. The AFFIRM study design. Am J Cardiol 79:1198, 1997

The VA Cooperative Study Investigators. Antiarrhythmics for maintenance of sinus in atrial fibrillation: Study design . (in preparation), 1998